S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.25 (+1.59%)
AAPL   116.79 (+0.85%)
MSFT   212.46 (+1.01%)
FB   266.63 (+1.81%)
GOOGL   1,487.90 (+1.52%)
AMZN   3,221.26 (+2.30%)
TSLA   448.16 (+4.46%)
NVDA   544.58 (+0.62%)
BABA   290.05 (-1.34%)
CGC   14.20 (-0.84%)
MU   47.92 (+2.04%)
GE   6.24 (+0.16%)
AMD   84.86 (+3.50%)
T   28.49 (-0.07%)
F   6.75 (+1.35%)
ACB   4.67 (+0.43%)
GILD   63.32 (+0.21%)
NFLX   527.51 (+5.50%)
DIS   123.31 (-0.62%)
BA   167.86 (+1.57%)
BAC   24.10 (+0.04%)
S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.25 (+1.59%)
AAPL   116.79 (+0.85%)
MSFT   212.46 (+1.01%)
FB   266.63 (+1.81%)
GOOGL   1,487.90 (+1.52%)
AMZN   3,221.26 (+2.30%)
TSLA   448.16 (+4.46%)
NVDA   544.58 (+0.62%)
BABA   290.05 (-1.34%)
CGC   14.20 (-0.84%)
MU   47.92 (+2.04%)
GE   6.24 (+0.16%)
AMD   84.86 (+3.50%)
T   28.49 (-0.07%)
F   6.75 (+1.35%)
ACB   4.67 (+0.43%)
GILD   63.32 (+0.21%)
NFLX   527.51 (+5.50%)
DIS   123.31 (-0.62%)
BA   167.86 (+1.57%)
BAC   24.10 (+0.04%)
S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.25 (+1.59%)
AAPL   116.79 (+0.85%)
MSFT   212.46 (+1.01%)
FB   266.63 (+1.81%)
GOOGL   1,487.90 (+1.52%)
AMZN   3,221.26 (+2.30%)
TSLA   448.16 (+4.46%)
NVDA   544.58 (+0.62%)
BABA   290.05 (-1.34%)
CGC   14.20 (-0.84%)
MU   47.92 (+2.04%)
GE   6.24 (+0.16%)
AMD   84.86 (+3.50%)
T   28.49 (-0.07%)
F   6.75 (+1.35%)
ACB   4.67 (+0.43%)
GILD   63.32 (+0.21%)
NFLX   527.51 (+5.50%)
DIS   123.31 (-0.62%)
BA   167.86 (+1.57%)
BAC   24.10 (+0.04%)
S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.25 (+1.59%)
AAPL   116.79 (+0.85%)
MSFT   212.46 (+1.01%)
FB   266.63 (+1.81%)
GOOGL   1,487.90 (+1.52%)
AMZN   3,221.26 (+2.30%)
TSLA   448.16 (+4.46%)
NVDA   544.58 (+0.62%)
BABA   290.05 (-1.34%)
CGC   14.20 (-0.84%)
MU   47.92 (+2.04%)
GE   6.24 (+0.16%)
AMD   84.86 (+3.50%)
T   28.49 (-0.07%)
F   6.75 (+1.35%)
ACB   4.67 (+0.43%)
GILD   63.32 (+0.21%)
NFLX   527.51 (+5.50%)
DIS   123.31 (-0.62%)
BA   167.86 (+1.57%)
BAC   24.10 (+0.04%)
Log in
NYSE:AMRX

Amneal Pharmaceuticals Stock Forecast, Price & News

$4.01
+0.13 (+3.35 %)
(As of 10/1/2020 12:00 AM ET)
Add
Compare
Today's Range
$3.91
Now: $4.01
$4.06
50-Day Range
$3.54
MA: $4.04
$4.48
52-Week Range
$2.40
Now: $4.01
$5.79
Volume717,973 shs
Average Volume1.60 million shs
Market Capitalization$1.20 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.37
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company has operations in the United States, Switzerland, India, Ireland, the United Kingdom and internationally. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.
Read More
Amneal Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.1Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.10 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone908-947-3120

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.63 billion
Cash Flow$1.14 per share
Book Value$1.16 per share

Profitability

Net Income$-361,920,000.00

Miscellaneous

Employees5,500
Market Cap$1.20 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$4.01
+0.13 (+3.35 %)
(As of 10/1/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amneal Pharmaceuticals (NYSE:AMRX) Frequently Asked Questions

How has Amneal Pharmaceuticals' stock price been impacted by Coronavirus?

Amneal Pharmaceuticals' stock was trading at $3.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AMRX shares have increased by 23.4% and is now trading at $4.01.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Amneal Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 2 sell ratings, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Amneal Pharmaceuticals
.

When is Amneal Pharmaceuticals' next earnings date?

Amneal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Amneal Pharmaceuticals
.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals Inc (NYSE:AMRX) posted its earnings results on Thursday, August, 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.10 by $0.03. The firm had revenue of $464.60 million for the quarter, compared to analyst estimates of $454.26 million. Amneal Pharmaceuticals had a positive return on equity of 30.64% and a negative net margin of 11.16%. The business's quarterly revenue was up 14.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.09 earnings per share.
View Amneal Pharmaceuticals' earnings history
.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals issued an update on its FY20 earnings guidance on Thursday, August, 6th. The company provided earnings per share (EPS) guidance of $0.45.0.60 for the period, compared to the Thomson Reuters consensus estimate of $0.56. The company issued revenue guidance of $1.875-1.975 billion, compared to the consensus revenue estimate of $1.91 billion.

What price target have analysts set for AMRX?

10 equities research analysts have issued 1 year target prices for Amneal Pharmaceuticals' shares. Their forecasts range from $3.00 to $7.00. On average, they anticipate Amneal Pharmaceuticals' stock price to reach $4.86 in the next twelve months. This suggests a possible upside of 21.1% from the stock's current price.
View analysts' price targets for Amneal Pharmaceuticals
.

Who are some of Amneal Pharmaceuticals' key competitors?

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Micron Technology (MU), Cisco Systems (CSCO), General Electric (GE), Opko Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), TherapeuticsMD (TXMD) and AbbVie (ABBV).

Who are Amneal Pharmaceuticals' key executives?

Amneal Pharmaceuticals' management team includes the following people:
  • Mr. Paul M. Bisaro, Exec. Chairman (Age 58)
  • Mr. Chirag K. Patel, Co-Founder & Co-Chairman (Age 52)
  • Mr. Chintu Patel, Co-Founder & Co-Chairman (Age 47)
  • Mr. Robert A. Stewart, Pres, CEO & Director (Age 51)
  • Ms. Nikita Shah, Sr. VP & Chief HR Officer (Age 41)

What is Amneal Pharmaceuticals' stock symbol?

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amneal Pharmaceuticals' stock price today?

One share of AMRX stock can currently be purchased for approximately $4.01.

How big of a company is Amneal Pharmaceuticals?

Amneal Pharmaceuticals has a market capitalization of $1.20 billion and generates $1.63 billion in revenue each year. The company earns $-361,920,000.00 in net income (profit) each year or $0.27 on an earnings per share basis. Amneal Pharmaceuticals employs 5,500 workers across the globe.

What is Amneal Pharmaceuticals' official website?

The official website for Amneal Pharmaceuticals is www.amneal.com.

How can I contact Amneal Pharmaceuticals?

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-947-3120 or via email at [email protected]

This page was last updated on 10/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.